NLE Cardiovascular Nursing — Inflammatory, Valvular and Vascular DisordersStudy Notes

Infective endocarditis (IE) is a serious infection of the cardiac endocardium and heart valves, typically caused by bacteremia seeding abnormal valvular tissue. The most common causative organisms are Streptococcus species (especially viridans streptococci and enterococci) and Staphylococcus aureus. The hallmark pathological finding is vegetation—clumps of fibrin, platelets, microorganisms, and inflammatory cells that form on valve surfaces and can embolize to distant organs. **Pathophysiology:** Damaged or prosthetic heart valves provide a substrate for bacterial adhesion. Risk factors include congenital heart defects, rheumatic valvular disease, prosthetic valve implantation, and critically, intravenous drug use (IVDU), which classically affects the tricuspid valve because organisms are injected directly into the venous circulation. Dental procedures, urologic interventions, and other invasive procedures create transient bacteremia that can seed the endocardium in susceptible individuals. **Clinical Manifestations:** Patients typically present with persistent fever, chills, and malaise lasting weeks to months. A new or changing heart murmur is a cardinal sign. Peripheral manifestations (stigmata of endocarditis) are important diagnostic clues: - **Janeway lesions:** painless, flat macules on palms and soles (small vessel emboli) - **Osler's nodes:** painful, tender nodules on the pads of fingers and toes (immune complex vasculitis) - **Splinter hemorrhages:** linear hemorrhages under the nails, resembling splinters - **Roth spots:** retinal hemorrhages with white or pale centers (septic emboli) - **Petechiae:** small red or purple spots on skin and mucous membranes Complicating embolic phenomena can cause acute stroke, meningitis, splenic infarction, or pulmonary embolism (if right-sided disease). Heart failure may develop from valve destruction or acute regurgitation. **Diagnostic Approach:** The **modified Duke criteria** guide diagnosis (requires 2 major or 1 major + 3 minor or 5 minor criteria). Blood cultures remain the gold standard—obtain at least three sets before initiating antibiotics. Echocardiography (preferably transesophageal) visualizes vegetations. **Nursing Implications and Management:** *Assessment and Monitoring:* Monitor temperature trends, heart sounds (documenting any murmurs), and signs of congestive heart failure (orthopnea, paroxysmal nocturnal dyspnea, peripheral edema). Assess for peripheral emboli (acute limb ischemia, hematuria, focal neurologic deficits). Monitor antibiotic levels (therapeutic drug monitoring) and renal function, as prolonged aminoglycoside use requires careful dosing adjustment. *Critical Nursing Intervention:* **Obtain blood cultures BEFORE initiating antibiotics.** This is high-yield NLE content. Organisms are more readily isolated from blood drawn before antimicrobial therapy begins. *Antibiotic Management:* Empiric or pathogen-directed IV antibiotics are administered for 4–6 weeks depending on organism and valve involvement. Compliance with prolonged IV therapy is challenging; ensure patient education on the necessity of completing the full course and accessing IV access (PICC line, peripherally inserted central catheter, or tunneled catheter if multiple peripheral sites are exhausted). *Patient Education:* Emphasize **antibiotic prophylaxis before dental work, urologic procedures, and gastrointestinal interventions** for high-risk patients (prosthetic valve, prior endocarditis, congenital cyanotic heart disease). For example, amoxicillin 2 g orally 30–60 minutes before dental procedures, or clindamycin for penicillin-allergic patients. *Nursing Diagnoses (NANDA):* Risk for Infection (related to bacteremia); Decreased Cardiac Output (related to valve insufficiency); Activity Intolerance (related to systemic infection); Deficient Knowledge (related to antibiotic prophylaxis and disease prevention). *Maslow-based Prioritization:* First address physiologic needs (cardiopulmonary stability, fever management); then safety (preventing embolic events, ensuring medication adherence); then education (prophylaxis, lifestyle modification).

**Pericarditis** is inflammation of the fibrous pericardium, the double-walled sac surrounding the heart. **Myocarditis** is inflammation of the myocardium itself. Both are often viral (enterovirus, parvovirus B19) but can be bacterial, autoimmune, or medication-related. These conditions are grouped together because they present as acute inflammatory processes with distinct nursing management. **Pericarditis: Pathophysiology and Clinical Presentation:** Inflammation of the pericardium causes pericardial effusion (fluid accumulation). The characteristic pain is **sharp and pleuritic (worse with deep breathing)** and **positional (worsens on lying flat, improves when sitting up and leaning forward)**. This positional relief is high-yield and distinguishes pericarditic pain from acute coronary syndrome (ACS), where pain does not improve with position changes. Physical examination often reveals a **pericardial friction rub**—a scratchy, three-component sound heard best with the diaphragm of the stethoscope. **Critical Complication: Cardiac Tamponade** If pericardial fluid accumulates rapidly or in large volume, it compresses the heart chambers, impeding venous filling and reducing cardiac output. This life-threatening emergency is characterized by **Beck's triad:** 1. **Hypotension** (reduced cardiac output) 2. **Muffled or distant heart sounds** (fluid dampening cardiac sounds) 3. **Jugular venous distention (JVD)** (elevated venous pressure from impaired venous return) Additionally, assess for **pulsus paradoxus**—an exaggerated drop in systolic BP (>10 mmHg) during inspiration. The mechanism is that during inspiration, venous return to the right heart increases, pushing the interventricular septum leftward and further compromising left ventricular filling. **Tamponade Management:** This is a medical emergency. Immediate intervention is **pericardiocentesis**—needle aspiration of pericardial fluid. The nurse prepares the patient, positions them upright or semi-upright, monitors cardiac rhythm and vital signs continuously, ensures sterile technique support, and documents the quantity and character of fluid obtained. After pericardiocentesis, re-assess Beck's triad components; improvement confirms the diagnosis. **Myocarditis: Pathophysiology and Clinical Presentation:** Viral myocarditis causes focal or diffuse inflammation and necrosis of myocardial cells. It can present as acute chest discomfort (often indistinguishable from ACS on ECG), but may be painless. Myocarditis can progress to acute dilated cardiomyopathy with severe systolic dysfunction and life-threatening arrhythmias. Fulminant myocarditis requires mechanical circulatory support (ECMO, ventricular assist device). **Diagnostic Clues:** Elevated troponin and BNP reflect myocardial injury and heart failure; ECG shows diffuse ST elevation (unlike the localized ST elevation of MI) or T-wave changes. Cardiac MRI can identify myocardial inflammation. **Nursing Management of Pericarditis and Myocarditis:** *Assessment:* Differentiate the character and timing of chest pain. Obtain baseline vital signs, including orthostatic BP. Auscultate for pericardial rub and assess for signs of tamponade (Beck's triad). Monitor cardiac rhythm for arrhythmias, especially ventricular ectopy in myocarditis. *Interventions:* Provide **rest and NSAIDs** (indomethacin, ibuprofen) for pain relief and inflammation reduction in uncomplicated pericarditis; corticosteroids are avoided initially as they may impair viral clearance. In myocarditis, activity restriction is critical until systolic function recovers. For tamponade, **prepare for emergency pericardiocentesis** by obtaining consent, positioning the patient, gathering equipment (20-gauge needle, drainage catheter, sterile gloves and drapes, 1% lidocaine), and ensuring immediate access to the cardiac catheterization lab or intensive care unit. *Monitoring Post-Pericardiocentesis:* Watch for recurrent effusion (Beck's triad returning, pericardial rub reappearing); repeat echocardiography assesses for fluid reaccumulation. Monitor for complications of the procedure: myocardial puncture (ST elevation, hemopericardium), arrhythmias, infection, or bleeding. *Nursing Diagnoses (NANDA):* Acute Pain (related to pericardial inflammation); Decreased Cardiac Output (related to pericardial effusion or myocardial dysfunction); Risk for Complications (related to pericardial tamponade); Anxiety (related to acute presentation and potential for hemodynamic compromise). *Patient Education:* Explain the positional nature of pain and that it improves with NSAIDs and position changes. Reinforce activity restriction and the importance of follow-up echocardiography to document resolution of effusion or recovery of myocardial function.

**Rheumatic Heart Disease (RHD)** is a chronic consequence of acute rheumatic fever (ARF), an autoimmune complication of untreated **group A beta-hemolytic streptococcal** (GABHS) pharyngitis. This remains a significant cause of valvular disease in the Philippines and other developing nations, particularly in children and young adults. **Pathophysiology of Rheumatic Fever:** Acute untreated streptococcal pharyngitis triggers an aberrant immune response. Antibodies produced against streptococcal antigens (particularly the M protein) cross-react with autoantigens in cardiac myosin, tropomyosin, and other heart proteins. This molecular mimicry initiates inflammation affecting the endocardium (endocarditis), myocardium, and pericardium (pancarditis). Acute rheumatic fever presents with fever, migratory polyarthritis (Aschoff bodies—granulomatous lesions—form in all three cardiac layers), skin manifestations (erythema marginatum, subcutaneous nodules), chorea (involuntary movements), and carditis. Repeated episodes of ARF, or a single severe episode, lead to permanent **fibrosis and scarring of the valve cusps**, most commonly the **mitral valve**, followed by the aortic valve. The valve becomes thick, rigid, and calcified, causing stenosis and/or regurgitation. This chronic scarring is the definition of rheumatic heart disease. **Prevention Strategy—Philippine Context:** Under Philippine health policy and the DOH NCD program, **prompt antibiotic treatment of strep throat is the cornerstone of RHD prevention.** A course of penicillin V (oral) or benzyl penicillin (IM) eradicates the streptococcus before ARF develops. Patients with a history of ARF or established RHD require **secondary prophylaxis**—long-term penicillin prophylaxis (monthly IM benzyl penicillin or daily oral penicillin V) to prevent recurrent episodes. The duration depends on whether carditis occurred and the presence of carditis without permanent valve disease (10 years); carditis with permanent valve disease (lifelong in some guidelines, at least until age 40). As a Filipino nurse, you are a key educator at the barangay and primary-care level (as part of the Community Health Team under RA 9173) in promoting early recognition and treatment of strep throat, preventing RHD in children. **Valvular Pathophysiology: Stenosis vs. Regurgitation** Valves function in two ways; failure results in two mechanisms: 1. **Stenosis** — The valve orifice narrows, obstructing forward blood flow. Pressure and volume back up upstream. The stenotic valve may have a systolic ejection murmur (aortic or pulmonary stenosis) or diastolic murmur (mitral or tricuspid stenosis) depending on which part of the cardiac cycle the valve opens against high pressure. 2. **Regurgitation (Insufficiency)** — The valve fails to close completely, allowing backflow into the upstream chamber during the valve's "closed" phase. This results in a holosystolic (pansystolic) murmur (mitral or tricuspid regurgitation) or early diastolic murmur (aortic or pulmonary regurgitation). Rheumatic disease typically causes **mitral stenosis** or **mitral regurgitation** (or both), less often aortic valve disease, and rarely tricuspid disease. **Mitral Stenosis:** **Pathophysiology:** The mitral valve narrows, obstructing left atrial-to-left ventricular flow. The left atrium dilates and develops high pressure; pressure backs up into the pulmonary vasculature, causing **pulmonary congestion and edema**, resulting in exertional dyspnea, orthopnea, and paroxysmal nocturnal dyspnea (PND). The elevated left atrial pressure and atrial stasis predispose to **atrial fibrillation (AF)**. **Clinical Findings:** Diastolic murmur at the apex (best heard in left lateral decubitus position with the stethoscope bell); opening snap (early diastolic sound as the stenotic valve opens abruptly); left atrial enlargement on chest X-ray and ECG. AF is common, increasing thromboembolic risk; anticoagulation (warfarin, DOAC) is indicated. **Hemodynamic Consequences:** The narrow mitral orifice limits cardiac output during exertion, causing **exertional dyspnea and fatigue.** Patients are typically in sinus rhythm or AF; stroke volume is fixed, so heart rate increases to maintain output, causing palpitations during exertion or AF with rapid ventricular response. **Mitral Regurgitation (Mitral Insufficiency):** **Pathophysiology:** The mitral valve fails to coapt fully, allowing blood to leak back into the left atrium during ventricular systole. The left atrium receives forward flow from the pulmonary veins plus backward regurgitant flow, increasing atrial volume and pressure. The left ventricle must pump the forward stroke volume plus the regurgitant volume, increasing LV preload and causing eccentric hypertrophy and dilation over time. **Clinical Findings:** Holosystolic (pansystolic) murmur at the apex, radiating to the axilla. The murmur begins with the first heart sound and continues through systole. Left ventricular hypertrophy and dilation on imaging. **Hemodynamic Consequences:** Initially well tolerated due to the compliant left atrium absorbing regurgitant flow at relatively low pressure. However, over years, LV dysfunction develops, eventually causing heart failure with reduced ejection fraction (HFrEF). **Aortic Stenosis:** **Pathophysiology:** Narrowing of the aortic valve orifice impedes left ventricular outflow. The LV must generate higher pressure to eject blood, causing concentric hypertrophy. Eventually, LV diastolic dysfunction and systolic dysfunction develop. **Classic Triad of Severe Aortic Stenosis:** 1. **Angina** — from LV hypertrophy and increased myocardial demand 2. **Syncope (or presyncope)** — from reduced cardiac output with exertion (cerebral hypoperfusion) or arrhythmias 3. **Exertional dyspnea** — from LV dysfunction and pulmonary edema **Clinical Findings:** Harsh systolic ejection murmur heard best at the right upper sternal border (aortic area), radiating to the carotid arteries. Delayed, diminished carotid upstroke (pulsus parvus et tardus); narrowed pulse pressure. Concentric LV hypertrophy on ECG and echocardiography. **Aortic Regurgitation (Aortic Insufficiency):** **Pathophysiology:** Failure of aortic valve closure allows diastolic runoff of aortic blood back into the LV. The LV receives its normal forward flow plus regurgitant flow, increasing preload and causing eccentric hypertrophy and dilation. **Clinical Findings:** Early diastolic (high-pitched, decreasing) murmur heard best at the left sternal border, with the patient leaning forward and in full expiration. The regurgitant volume is large, causing a **widened pulse pressure** (elevated systolic, low diastolic), resulting in bounding pulses (water-hammer or Corrigan pulses). The wide pulse pressure is so characteristic it is high-yield NLE content. **Associated Physical Signs of Chronic Aortic Regurgitation:** - **Bounding pulses** (hyperdynamic pulse) - **Wide pulse pressure** - **Quincke's sign** (capillary pulsations in the nail beds) - **De Musset's sign** (head bobbing with systole) - **Duroziez's sign** (femoral artery systolic and diastolic murmur) **Medical and Surgical Management of Valvular Disease:** *Pharmacologic Therapy:* - **Diuretics** (furosemide) for pulmonary or systemic congestion - **ACE inhibitors/ARBs** (enalapril, losartan) to reduce LV afterload in regurgitant lesions, slowing progression - **Beta-blockers** for rate control in AF or to reduce contractility and afterload stress - **Anticoagulation** with warfarin (INR 2–3) or DOAC for AF - **Avoid** vasodilators and inotropes in aortic stenosis (they can precipitate syncope or hemodynamic collapse) *Surgical Intervention:* - **Valve repair** (preferred when feasible, especially for mitral valve) preserves native valve and avoids anticoagulation if a mechanical prosthesis is not needed - **Valve replacement** with either: - **Mechanical prosthesis** (durable, 20–30+ year lifespan) requires **lifelong anticoagulation** with warfarin (target INR 2.5–3.5 depending on valve type and position); high thromboembolic risk without anticoagulation - **Bioprosthetic valve** (animal-derived or homograft) has lower thromboembolic risk and does **not require long-term anticoagulation** (except bridging in AF), but has limited durability (10–15 years) and requires eventual reoperation. Ideal for older patients or those in whom anticoagulation is contraindicated. **Nursing Implications for Valvular Disease:** *Assessment:* Characterize murmurs by timing (systolic vs. diastolic), location, radiation, and quality. Assess for signs of heart failure (orthopnea, PND, peripheral edema, hepatomegaly). Monitor for AF (pulse irregularity, palpitations) and thromboembolic signs (sudden leg swelling, chest pain, neurologic deficit). In severe stenotic lesions, monitor for syncope or presyncope triggers. *Nursing Diagnoses (NANDA):* Decreased Cardiac Output (related to valvular stenosis/regurgitation); Ineffective Tissue Perfusion (related to emboli or reduced forward flow); Activity Intolerance (related to cardiac compromise); Risk for Infection (endocarditis) in damaged valves; Anxiety (related to chronic disease and surgical planning). *Antibiotic Prophylaxis:* Patients with significant valvular disease (stenosis, regurgitation) require prophylactic antibiotics before dental, GI, and genitourinary procedures to prevent endocarditis seeding. *Pre- and Post-Operative Care for Valve Surgery:* - **Preoperative:** Optimize cardiac function (diuretics, afterload reduction); baseline ECG, chest X-ray, blood work (coagulation studies, blood typing for possible transfusion); teach about postoperative expectations, incentive spirometry, early ambulation, pain control. - **Postoperative:** Monitor for bleeding (especially with mechanical prosthesis and anticoagulation); assess for dysrhythmias (bypass-related); monitor for prosthetic valve function (new murmur, dyspnea, syncope may indicate thrombosis or paravalvular leak); ensure compliance with anticoagulation if mechanical valve; monitor renal function and electrolytes (diuretics, vasodilators); facilitate cardiac rehabilitation. *Patient Education:* - Emphasize **antibiotic prophylaxis** before dental work and invasive procedures. - For **mechanical valve** patients, teach about **lifelong warfarin compliance,** dietary vitamin K consistency (do not avoid but maintain steady intake), and signs of bleeding (blood in urine, stool, epistaxis) or thrombosis (sudden dyspnea, chest pain, syncope). - Promote activity as tolerated; rest if dyspnea or chest discomfort develops. - Teach about AF symptoms (palpitations, irregular pulse) and when to seek care. - In the Philippine context, reinforce the importance of early strep throat treatment and secondary prophylaxis in children and young adults to prevent rheumatic heart disease.

**Hypertension (HTN)** is persistently elevated arterial blood pressure. It is called the **"silent killer"** because the majority of hypertensive individuals are asymptomatic until end-organ damage occurs. Under the current **2017 ACC/AHA guidelines**, which are increasingly adopted in the Philippines, BP categories are: - **Normal:** <120/80 mmHg - **Elevated:** 120–129/<80 mmHg - **Stage 1 HTN:** 130–139/80–89 mmHg - **Stage 2 HTN:** ≥140/90 mmHg **Important Note for NLE Preparation:** The **older JNC 7 (Seventh Report of the Joint National Committee) definition**, which classified HTN as ≥140/90 mmHg, is still widely used in Philippine clinical practice and may appear in NLE questions. Be aware that **both frameworks coexist.** When answering NLE questions, check the context to determine which standard is being applied. **Pathophysiology: Primary vs. Secondary Hypertension** **Primary (Essential) Hypertension (90–95% of cases):** No single identifiable cause; results from a complex interplay of genetic predisposition and environmental factors: - **Genetic factors:** Familial clustering; twin studies show 60–70% heritability - **Environmental factors:** High dietary sodium intake, obesity, excessive alcohol consumption, sedentary lifestyle, chronic stress, and smoking - **Pathophysiology:** Dysregulation of the renin-angiotensin-aldosterone system (RAAS), sympathetic nervous system overactivity, endothelial dysfunction (reduced nitric oxide production), increased arterial stiffness, and natriuretic peptide system abnormalities. Renal sodium retention and increased cardiac output and peripheral vascular resistance perpetuate elevated BP. **Secondary Hypertension (5–10% of cases):** Identifiable underlying cause, such as: - **Renal disease:** Chronic kidney disease (CKD), renovascular disease, renal artery stenosis (RAS) - **Endocrine:** Pheochromocytoma (catecholamine excess), hyperthyroidism, Cushing's syndrome (excess cortisol), primary hyperaldosteronism - **Vascular:** Aortic coarctation (narrowing of the descending aorta; HTN in upper extremities, hypotension in lower extremities) - **Medications:** Oral contraceptives, NSAIDs, sympathomimetic amines, corticosteroids, decongestants - **Pregnancy-related:** Gestational HTN, preeclampsia, eclampsia Secondary HTN should be suspected in young patients with sudden-onset severe HTN, those resistant to multiple antihypertensives, or those with clinical clues (flank pain and hypokalemia suggesting hyperaldosteronism, or episodic severe headache and diaphoresis suggesting pheochromocytoma). **Hypertensive Target-Organ Damage (Complications):** Chronic HTN causes structural and functional damage to organs: - **Cardiac:** Left ventricular hypertrophy (LVH) from sustained pressure overload, leading to diastolic dysfunction, systolic dysfunction, heart failure with reduced or preserved ejection fraction (HFrEF or HFpEF) - **Cerebrovascular:** Ischemic stroke, hemorrhagic stroke, hypertensive encephalopathy - **Renal:** CKD, proteinuria, eventual dialysis dependence (HTN is a leading cause of CKD in the Philippines) - **Ocular:** Hypertensive retinopathy, microaneurysms, dot-blot hemorrhages, cotton-wool spots, papilledema in severe HTN - **Vascular:** Atherosclerosis acceleration, aortic aneurysm, peripheral arterial disease **Hypertensive Crisis:** A **hypertensive crisis** is defined as BP persistently above 180/120 mmHg. It is subdivided into: - **Hypertensive urgency:** Severely elevated BP (>180/120) **without evidence of acute end-organ damage.** Symptoms may include headache, anxiety, or epistaxis but no target-organ damage on assessment. Management is to **reduce BP gradually over hours** with oral agents, avoiding precipitous drops that can cause stroke or MI. - **Hypertensive emergency:** Severely elevated BP **with acute end-organ damage** such as hypertensive encephalopathy (severe headache, confusion, seizures, pulmonary edema), acute coronary syndrome, acute MI, aortic dissection, or acute kidney injury. Management requires **IV antihypertensives with intensive monitoring** to reduce BP by 10–15% in the first hour and 25% within 24 hours, avoiding excessive reduction that causes ischemia. **Antihypertensive Pharmacology: Drug Classes and Nursing Considerations** 1. **Diuretics** (thiazide and loop diuretics) - **Mechanism:** Increase renal sodium and water excretion, reducing plasma volume and cardiac output - **Examples:** Hydrochlorothiazide (HCTZ), chlorthalidone, furosemide - **First-line agent:** HCTZ or chlorthalidone for uncomplicated HTN - **Nursing Considerations:** - Monitor **serum electrolytes** (hypokalemia, hyponatremia, hypomagnesemia) - Monitor **glucose** (thiazides can worsen glucose control) - Monitor **uric acid** (diuretics can precipitate gout) - Orthostatic hypotension (especially with loop diuretics); educate patient to rise slowly - Ototoxicity with high-dose loop diuretics 2. **ACE Inhibitors and Angiotensin Receptor Blockers (ARBs)** - **Mechanism:** Block the renin-angiotensin-aldosterone system, reducing angiotensin II-mediated vasoconstriction and aldosterone-mediated sodium retention - **ACE Examples:** Enalapril, lisinopril, ramipril, quinapril - **ARB Examples:** Losartan, valsartan, candesartan, azilsartan - **First-line agents** for HTN, especially in diabetics and those with CKD (renal protective) - **Nursing Considerations:** - **ACE Inhibitor Adverse Effect:** **Dry, persistent cough** (10–20% of patients; due to bradykinin accumulation); if bothersome, switch to ARB - **Angioedema** (rare but serious; more common with ACE inhibitors); educate about throat swelling or difficulty breathing - **Hyperkalemia** (risk especially with renal impairment or concurrent diuretics); monitor K+ and creatinine - **Contraindicated in pregnancy** (especially second and third trimesters; teratogenic) - **First-dose hypotension** (especially in volume-depleted patients); start low dose and titrate up 3. **Calcium Channel Blockers (CCBs)** - **Mechanism:** Inhibit calcium influx into vascular smooth muscle and cardiac conduction tissue, causing vasodilation and reduced contractility - **Dihydropyridine Examples (peripheral vascular selectivity):** Amlodipine, nifedipine (immediate and extended release), felodipine, nisoldipine - **Non-dihydropyridine Examples (cardiac selectivity):** Diltiazem, verapamil - **Nursing Considerations:** - **Peripheral edema** (especially dihydropyridines; due to preferential afferent arteriole dilation in capillaries); educate that this is usually benign and improves with leg elevation but does NOT indicate fluid overload (diuretics are ineffective) - **Headache, dizziness, flushing** (especially with dihydropyridines) - **Reflex tachycardia** (dihydropyridines cause peripheral vasodilation → compensatory heart rate increase); combined with beta-blocker to mitigate - **Gingival hyperplasia** (particularly diltiazem and verapamil); educate on meticulous oral hygiene - **Non-dihydropyridines (diltiazem, verapamil) cause bradycardia and AV block** (negative chronotropic and dromotropic effects); contraindicated in severe bradycardia or AV block - **Grapefruit juice interaction** (inhibits CYP3A4 metabolism, increasing drug levels); avoid concurrent consumption 4. **Beta-Blockers** - **Mechanism:** Antagonize beta-adrenergic receptors, reducing heart rate, contractility, and cardiac output; decrease renin release - **Examples:** Metoprolol, atenolol, propranolol, labetalol (combined alpha/beta-blocker) - **Less preferred as first-line** for uncomplicated HTN in recent guidelines but useful in HTN with CAD, post-MI, HF with reduced ejection fraction, or AF - **Nursing Considerations:** - **Bradycardia and fatigue** (limiting in some patients) - **Reduced exercise tolerance** (blunt heart rate response to exertion) - **Erectile dysfunction** - **Hyperglycemia** (masks hypoglycemia symptoms in diabetics; may worsen glucose control) - **Bronchospasm** (non-selective beta-blockers contraindicated in asthma/COPD) - **CRITICAL: Do not abruptly discontinue** (sudden withdrawal causes rebound hypertension, tachycardia, and risk of MI); taper slowly over 7–14 days 5. **Alpha-Blockers** - **Mechanism:** Block alpha-1 adrenergic receptors, causing peripheral vasodilation - **Examples:** Doxazosin, prazosin, terazosin - **Not first-line** but useful in HTN with concurrent benign prostatic hyperplasia (BPH) - **Nursing Consideration:** **First-dose syncope** (severe orthostatic hypotension after first dose); give first dose at bedtime and advise lying down for several hours 6. **Direct Vasodilators** - **Examples:** Hydralazine, minoxidil - **Mechanism:** Direct relaxation of arterial smooth muscle - **Reserved for resistant HTN or hypertensive emergencies** (IV hydralazine) or specific situations (hydralazine in pregnancy, minoxidil in severe refractory HTN) - **Nursing Considerations:** Hydralazine may cause lupus-like syndrome; reflex tachycardia and fluid retention (usually combined with diuretics and beta-blockers); minoxidil causes hirsutism 7. **Direct Renin Inhibitor** - **Aliskiren:** Blocks renin directly - **Not preferred** due to minimal additional benefit over ACE inhibitors/ARBs and potential adverse effects; risk of hyperkalemia, renal dysfunction, and angioedema **Nursing Management and Patient Education: The Cornerstone of HTN Control** *Assessment and Monitoring:* - **Correct BP measurement technique:** - Use **appropriate cuff size** (bladder encircles 80% of arm circumference; too small cuff falsely elevates BP) - Patient **seated with arm at heart level**, feet flat on floor, **rested for 5 minutes** before measurement - Avoid caffeine, nicotine, and exercise for 30 minutes prior - Take **two measurements 1–2 minutes apart;** average them - Measure in **both arms** on initial visit; use arm with higher reading for follow-up - Check **standing BP** to assess for orthostatic hypotension (especially in elderly or those on antihypertensives) - Monitor for **target-organ damage signs:** Check for LVH (ECG, echocardiography), proteinuria (urinalysis), retinopathy (fundoscopic exam), carotid bruits (auscultation) - Assess for **medication adverse effects** at each visit - Obtain **baseline renal function (creatinine, eGFR), electrolytes, glucose, lipid panel,** and **urine protein** before initiating therapy; repeat annually or as indicated *Lifestyle Modifications (Non-pharmacologic Management):* These are **first-line for elevated BP and stage 1 HTN,** and **adjunctive for stage 2 HTN on medications.** Emphasize that lifestyle changes can **prevent or delay need for medications** and **enhance medication efficacy.** 1. **Dietary Sodium Restriction:** - Target **<2,400 mg/day sodium** (approximately 1 teaspoon salt or 6 g NaCl) - In the Philippine context, educate about high-sodium processed foods (bagoong, patis, salt-cured fish, instant noodles, canned goods), popular condiments, and suggest fresh produce, legumes, and home-prepared meals - DASH diet (Dietary Approaches to Stop Hypertension): rich in fruits, vegetables, whole grains, lean proteins; reduces BP by 8–14 mmHg 2. **Weight Loss:** - Target **5–10% weight reduction in overweight/obese individuals** - Each kilogram of weight loss can reduce BP by approximately 1 mmHg - Promote regular physical activity as part of weight management program 3. **Physical Activity/Exercise:** - **150 minutes moderate-intensity aerobic activity per week** (brisk walking, jogging, cycling, swimming) or **75 minutes vigorous activity** - Can reduce BP by 5–8 mmHg; improves overall cardiovascular health and weight management - Resistance training 2–3 days/week may also help - Educate that regular walking and household activities (e.g., gardening) count 4. **Alcohol Moderation:** - Limit to **≤2 drinks/day for men and ≤1 drink/day for women** (1 drink = 12 oz beer, 5 oz wine, 1.5 oz spirits) - Excessive alcohol elevates BP and increases cardiovascular risk 5. **Smoking Cessation:** - **Smoking cessation is urgent.** Even one cigarette acutely raises BP; chronic smoking contributes to HTN pathophysiology and accelerates atherosclerosis - Refer to smoking cessation programs; prescribe nicotine replacement, bupropion, or varenicline as indicated 6. **Stress Management:** - Meditation, yoga, biofeedback, or counseling may help - Regular physical activity also reduces stress *Medication Adherence:* This is a **major barrier to HTN control.** Patients often feel well and do not perceive benefit, leading to discontinuation. Emphasize: - "Hypertension is called the 'silent killer' because you may feel fine even with high blood pressure. The goal is to **prevent future strokes, heart attacks, and kidney disease**, not to relieve immediate symptoms." - Simplified dosing schedules (once-daily formulations preferred) - Combination pills (ACE inhibitor + diuretic, for example) reduce pill burden - Patient education about long-term benefits - Regular follow-up and BP monitoring at home (home BP monitoring improves adherence and provides more accurate readings than office BP) *Nursing Diagnoses (NANDA):* - Ineffective health maintenance (related to lack of awareness of asymptomatic HTN and consequences) - Deficient knowledge (related to HTN pathophysiology, treatment, and lifestyle modification) - Ineffective medication adherence (related to feeling well despite high BP) - Risk for decreased cardiac output (related to target-organ damage) - Imbalanced nutrition: more than body requirements (related to obesity contributing to HTN) *Philippine Health System Context (RA 9173 and DOH NCD Program):* Under the DOH's **PhilPEN (Philippine Health Program on Non-Communicable Diseases)**, hypertension screening and management are integrated into barangay health stations and primary-care facilities. As a community health nurse, you are responsible for: - **Screening:** Opportunistic BP measurement in patients attending clinics - **Health promotion:** Teaching about sodium restriction, weight loss, exercise, and smoking cessation - **Medication distribution and adherence monitoring** at the barangay level (ensuring patient compliance with antihypertensives) - **Referral:** Escalating complex cases (secondary HTN, resistant HTN, hypertensive crisis) to secondary/tertiary facilities - **Documentation and surveillance:** Recording HTN cases for health data and population-level monitoring

Peripheral vascular disease encompasses disorders of the arteries and veins outside the heart and coronary circulation. The key nursing principle is to **differentiate arterial from venous insufficiency** because their management is opposite: **arterial = dangle (keep legs dependent); venous = elevate.** ## **PERIPHERAL ARTERIAL DISEASE (PAD)** **Pathophysiology:** PAD is atherosclerotic narrowing or occlusion of the arteries supplying the limbs (typically lower extremities). Progressive stenosis reduces blood flow distal to the lesion, causing tissue ischemia during increased metabolic demand (exercise) and eventual rest ischemia if severe. **Risk Factors:** Atherosclerotic risk factors: age, male gender, smoking (strongest modifiable risk factor), diabetes, hypertension, hyperlipidemia, chronic kidney disease. **Clinical Presentation:** **Intermittent Claudication (IC):** The hallmark symptom is **pain in the calf, thigh, or buttock that occurs with walking and is relieved by stopping and resting** (typically within 5–10 minutes). The distance walked before pain develops is reproducible and is called the **claudication distance.** Pain worsens walking uphill or hurrying and improves with rest. This distinguishes claudication from other causes of leg pain. As disease progresses, claudication distance shortens, indicating worsening arterial stenosis. **Assessment (Arterial Insufficiency Signs):** - **Leg pain characteristics:** - **Worsens with elevation** (raising the leg reduces gravity-assisted blood flow, worsening ischemia) - **Improves when legs are dependent** (dangling off the bed or walking increases blood flow by gravity) - This is the **opposite of venous pain**, a key differentiation point - **Diminished or absent pulses:** Palpate femoral, popliteal, dorsalis pedis (DP), and posterior tibial (PT) pulses; compare both legs; weak or absent pulses indicate proximal stenosis - **Skin findings:** Cool, pale, or cyanotic skin; shiny, thin, hairless skin (loss of hair on legs and feet from chronic ischemia); nails may be thickened and dystrophic - **Ulcers:** **Painful, "punched-out" ulcers** on the toes, heels, or pressure points (in contrast to venous ulcers, which are shallow and around the medial malleolus) - **Gangrene:** In severe ischemia, tissue necrosis and potential limb loss **Diagnostic Approach:** - **Ankle-brachial index (ABI):** Ratio of systolic BP in the ankle (dorsalis pedis or posterior tibial artery) to systolic BP in the arm (brachial artery). Normal ABI is 0.9–1.1; **ABI <0.9 suggests PAD**; **ABI <0.4 suggests critical limb ischemia.** ABI >1.4 suggests rigid, calcified vessels (seen in diabetes and CKD). - **Duplex ultrasound:** Non-invasive imaging showing arterial stenosis and peak systolic velocity - **Computed tomographic angiography (CTA) or magnetic resonance angiography (MRA):** For detailed anatomic assessment before intervention - **Treadmill exercise test:** Reproduces claudication symptoms and objectively measures claudication distance **Management:** *Conservative Management (First-line):* - **Walking program:** Exercise to the point of claudication pain, then rest. Over weeks to months, **collateral circulation develops**, improving walking distance and symptoms. This is counterintuitive but crucial: we encourage walking despite pain, with rest breaks. Walking 30–60 minutes, 3–5 days per week, can improve claudication distance significantly. - **Smoking cessation:** Single most important modifiable factor; significantly slows disease progression - **Control risk factors:** Manage diabetes, hypertension, dyslipidemia; antiplatelet therapy (aspirin 81–325 mg daily or clopidogrel 75 mg daily) - **Foot care:** Daily foot inspection (using a mirror if necessary); keep feet clean and dry; wear comfortable, well-fitting shoes; avoid barefoot walking; seek medical attention for any cuts, blisters, or infections immediately - **Keep legs in dependent (dangling) position** when resting to maximize gravity-assisted blood flow - **Avoid crossing legs,** tight stockings, or restrictive clothing that impedes blood flow *Pharmacologic Therapy:* - **Antiplatelets:** Aspirin or clopidogrel reduce thrombotic risk - **Cilostazol (Pletal):** Phosphodiesterase-3 inhibitor; improves claudication distance by increasing blood flow and reducing platelet aggregation. Dose is 100 mg twice daily (50 mg if using certain CYP3A4 inhibitors). Improves claudication distance by 25–50% in many patients. Contraindicated in heart failure. - **Statins:** Reduce cardiovascular events regardless of LDL cholesterol - **ACE inhibitors:** Cardioprotective *Interventional Procedures:* - **Percutaneous transluminal angioplasty (PTA) with or without stenting:** For focal stenoses or occlusions causing significant claudication or critical limb ischemia - **Bypass surgery:** Femoral-popliteal or femoral-distal bypass using autogenous vein (saphenous vein) or synthetic graft for more extensive disease - Reserved for **critical limb ischemia** (rest pain, ulcers, gangrene) or **claudication severely limiting quality of life** despite conservative measures **Nursing Care:** - Reinforce regular walking program; encourage patient to walk to the point of pain, rest, then resume - Teach foot care meticulously (daily inspection, hygiene, appropriate footwear) - Educate about smoking cessation - Monitor BP and diabetes control - Assess claudication distance at each visit (using standardized treadmill test or reported walking distance) - Prepare for intervention (imaging, procedure) as indicated - Post-intervention: Monitor surgical sites for infection, assess pulses and limb perfusion, ensure graft patency **Nursing Diagnoses (NANDA):** - Activity Intolerance (related to claudication pain during exercise) - Risk for Impaired Skin Integrity (related to chronic ischemia) - Ineffective Peripheral Tissue Perfusion (related to arterial stenosis) - Deficient Knowledge (related to foot care and activity modification) ## **CHRONIC VENOUS INSUFFICIENCY (CVI)** **Pathophysiology:** Venous insufficiency results from **incompetent venous valves** (from DVT, venous obstruction, or primary valve weakness) or **venous obstruction**, impeding blood return from the legs. Venous pressure remains elevated, causing valve reflux and progressive venous hypertension. Blood pools in the legs, leading to edema, skin changes, and ulcer formation. **Clinical Presentation:** **Leg Symptoms (Opposite of Arterial):** - **Pain improves with elevation** (raising the leg reduces venous pressure and promotes drainage) - **Pain worsens with prolonged standing or sitting** (increased venous pooling) - **Heaviness, aching, fatigue** of the legs, especially at the end of the day - **Swelling/edema** of the ankle and lower leg, worse after prolonged standing, improving with leg elevation and overnight rest - **Cramping** and **restless leg sensation** (sometimes) **Skin and Tissue Changes (Hemosiderin Deposition):** - **Brownish or reddish discoloration** (hemosiderin staining from chronic venous hypertension and RBC extravasation; gives a rust-colored appearance) - **Lipodermatosclerosis:** Thickened, hardened skin from fibrosis (inverted bottle appearance of the lower leg) - **Varicose veins:** Dilated, tortuous veins; may be visible or palpable - **Skin atrophy,** hyperpigmentation **Venous Ulcers:** - **Location:** Around the **medial malleolus** (inside ankle bone), the area of highest venous pressure - **Appearance:** **Shallow, moist ulcers** with irregular borders (in contrast to arterial ulcers, which are punched-out and painful) - **Painless or minimally painful** (paradoxically) - **Associated with edema,** hemosiderin staining, and varicose veins **Diagnostic Approach:** - **Clinical presentation** (edema, discoloration, ulcer location) - **Duplex ultrasound:** Assesses valve competence and venous reflux; identifies obstruction - **Venography:** Reserved for suspected chronic venous obstruction **Management:** *Conservative Management (First-line):* - **Leg elevation:** **Elevate legs above the heart level** several times daily (lying with feet on pillows higher than heart) to promote venous drainage. This is the cornerstone and **opposite of arterial care (which requires dependent position).** - **Compression stockings:** Graduated compression (15–20 mmHg mild; 20–30 mmHg moderate; 30–40 mmHg strong) helps push blood upward against gravity. Educate patient on donning stockings in the morning before standing and removing before bed. Compliance is challenging but essential. - **Ambulation:** Walking promotes calf muscle contraction ("second heart" effect), propelling blood upward - **Avoid prolonged sitting or standing** without leg elevation or compression - **Avoid leg crossing** and tight clothing that impedes blood flow - **Leg exercise:** Ankle pumping and calf raises promote venous return - **Weight management** (obesity increases venous pressure) - **Smoking cessation** *Pharmacologic Therapy:* - **Venotonics:** Diosmin, flavonoids (e.g., Aesculus hippocastanum—horse chestnut seed extract); improve vein tone and reduce edema; evidence is mixed - **Topical agents:** For ulcer healing, use modern dressings (hydrocolloids, alginates, foams) and address underlying infection if present *Interventional Procedures:* - **Compression therapy alone** manages most CVI - **Endovenous ablation (laser or radiofrequency):** For incompetent saphenous vein - **Sclerotherapy:** Injection of sclerosing agent to obliterate varicose veins (cosmetic) - **Venous bypass or valve reconstruction:** Rarely used; limited success **Nursing Care:** - Educate extensively on **leg elevation** (counterintuitive for patients with leg pain) - Assist with **compression stocking fitting and education** on proper application and care - Assess skin integrity regularly; prevent and manage ulcers with sterile dressing changes - Promote walking and ankle exercises - Monitor for signs of deep vein thrombosis (unilateral swelling, warmth, calf tenderness, Homan's sign) - Teach about avoiding prolonged immobility **Nursing Diagnoses (NANDA):** - Ineffective Peripheral Tissue Perfusion (related to venous insufficiency and valve incompetence) - Risk for Impaired Skin Integrity (related to chronic venous hypertension) - Deficient Knowledge (related to compression therapy and leg elevation) ## **CRITICAL DIFFERENTIATION: ARTERIAL VS. VENOUS INSUFFICIENCY** | Feature | Arterial Insufficiency | Venous Insufficiency | |---------|------------------------|-----------------------| | **Pain Location** | Calf, thigh, buttock (claudication) | Ankle, lower leg (aching, heaviness) | | **Pain with Exercise** | Claudication pain (walking triggers pain) | Improves with walking | | **Pain with Leg Elevation** | **Worsens** | **Improves** | | **Pain with Leg Dependent** | **Improves** | **Worsens** | | **Skin Color** | Pale, cool, cyanotic | Brownish/reddish (hemosiderin), warm | | **Edema** | Minimal unless critical ischemia | Significant, especially ankle | | **Ulcer Location** | Toes, heels, pressure points | Medial malleolus | | **Ulcer Appearance** | Painful, punched-out, deep | Shallow, moist, minimally painful | | **Pulses** | Diminished or absent | Normal | | **Skin Findings** | Hairless, shiny, thin | Thickened, varicose veins, discoloration | | **Management Position** | **Dangle (keep dependent)** | **Elevate (above heart)** | | **Activity** | Walking to pain point for collateral development | Regular walking to promote venous return | **Mnemonic: ARTERIAL = DANGLE; VENOUS = ELEVATE** **Nursing Diagnoses (NANDA) for PAD:** - Ineffective Peripheral Tissue Perfusion (related to arterial stenosis) - Activity Intolerance (related to claudication pain) - Risk for Impaired Skin Integrity (related to chronic ischemia) - Deficient Knowledge (related to foot care and walking program) **Nursing Diagnoses (NANDA) for CVI:** - Ineffective Peripheral Tissue Perfusion (related to venous valve incompetence) - Risk for Impaired Skin Integrity (related to venous stasis and edema) - Deficient Knowledge (related to compression and elevation) --- ## **BUERGER'S DISEASE (THROMBOANGIITIS OBLITERANS)** **Definition:** Buerger's disease is a **non-atherosclerotic, inflammatory, segmental occlusive disease** of the small and medium-sized arteries and veins of the extremities. It is most prevalent in young men (30–45 years old) with a **strong association with tobacco use.** **Pathophysiology:** The exact cause is unknown, but tobacco is essential to disease development—smokers with Buerger's disease have a 90–95% association. The disease is characterized by acute inflammation of the vessel wall (vasculitis) with subsequent thrombosis. It can affect upper and lower extremities and may progress to gangrene requiring amputation. **Clinical Presentation:** - **Intermittent claudication** of the distal lower extremity or upper extremity - **Rest pain** and **ischemic ulcers** in advanced disease - **Superficial thrombophlebitis** (migratory, affecting multiple superficial veins; a distinguishing feature) - **Raynaud's phenomenon** (discussed below) - **Absence of atherosclerotic disease** on angiography; the disease shows segmental occlusions with skip lesions (normal vessel segments between occlusions) **Critical Management Principle:** **SMOKING CESSATION IS THE SINGLE MOST IMPORTANT INTERVENTION.** There is no evidence that amputation rates decrease without smoking cessation. Complete cessation can halt disease progression and prevent amputation; continued smoking leads to progressive disease and eventual limb loss. **Other Management:** - Antiplatelet therapy (aspirin) - Vasodilators (calcium channel blockers) may help - Bypass surgery for critical limb ischemia (but recurrent thrombosis if patient continues smoking) - Amputation in irreversible ischemia (gangrene) **Nursing Care:** - **Urgent smoking cessation counseling** and referral to cessation programs - Aggressive foot care - Pain management - Prepare for intervention or amputation as indicated - Psychological support for young patients facing potential limb loss --- ## **RAYNAUD'S PHENOMENON** **Definition:** Raynaud's phenomenon is **episodic vasospasm of the digital arteries** triggered by **cold exposure or emotional stress,** causing **reversible color changes** in the fingers and toes. **Classic Color Sequence (High-Yield NLE):** 1. **White (pallor):** Initial vasoconstriction, causing blanching and loss of blood flow 2. **Blue/Purple (cyanosis):** Deoxygenation of static blood in the digit 3. **Red (rubor):** Reactive hyperemia as vasospasm resolves and blood returns The sequence typically progresses over minutes to hours; not all three colors are always present, but **white then red** is most common. Patients report **numbness and tingling** during the white phase and **pain/throbbing** during the red phase (rewarming). **Distinction Between Primary and Secondary Raynaud's:** - **Primary Raynaud's (Raynaud's disease):** Idiopathic; more common; better prognosis; occurs in 5–10% of the general population; benign course with no tissue necrosis or ulceration - **Secondary Raynaud's (Raynaud's phenomenon):** Associated with underlying connective tissue disease (scleroderma, systemic lupus erythematosus, rheumatoid arthritis, Sjögren's syndrome); more severe; risk of digital ulceration, tissue loss **Triggers:** - **Cold exposure** (most common): touching cold water, exposure to cold air, working in cold environments - **Emotional stress:** anxiety, sudden fright - **Vibration:** from power tools - **Smoking:** nicotine causes vasoconstriction **Clinical Presentation:** - Finger color changes in sequence (white → blue → red) - **Numbness and paresthesia** during white phase - **Pain and throbbing** during red phase - Usually **no tissue damage** in primary disease; **ulceration and gangrene possible in secondary disease** - Typically affects fingers; toes may be involved; nose and ears rarely affected **Diagnostic Approach:** - **Clinical history** of color changes and triggers - **Nailfold capillaroscopy:** Examines capillaries under magnification; abnormalities (megacapillaries, dilations, dropouts) suggest secondary Raynaud's and connective tissue disease - **Serologic testing** (ANA, anti-Scl-70, anticentromere antibodies) if secondary disease suspected **Management:** *Conservative Management (First-line):* - **Keep hands and body warm:** Wear insulated gloves when exposed to cold; maintain core body temperature - **Avoid cold exposure:** Limit time in cold environments; use cold water cautiously - **Stress reduction:** Relaxation techniques, meditation - **Avoid vasoconstrictors:** Stop smoking (nicotine); avoid decongestants, ergot derivatives, beta-blockers (if possible) - **Protect digits:** Avoid trauma; keep nails trimmed *Pharmacologic Therapy:* Reserved for **severe or secondary Raynaud's with frequent disabling attacks or tissue damage risk.** - **Calcium channel blockers (CCBs):** Nifedipine (immediate or extended release) is first-line; reduces frequency and severity of attacks by 60–70% in some patients. Dose is typically 30–60 mg daily. Benefits take 2–3 weeks. - **Alpha-blockers:** Prazosin (less evidence) - **Topical nitrates:** Nitroglycerol paste applied to affected digits (limited evidence) - **Phosphodiesterase-5 inhibitors:** Sildenafil (for secondary Raynaud's with digital ulcers) *Surgical/Interventional:* - **Digital sympathectomy:** Surgical interruption of sympathetic nerves to the digits; results are temporary **Nursing Care:** - Educate about **avoiding cold exposure** and keeping hands warm - Teach **stress management** - Counsel on **smoking cessation** - For severe cases on CCB, monitor BP (may cause hypotension) - Assess for signs of digital ulceration, infection, or gangrene, especially in secondary disease - Reassure patients with primary Raynaud's about the benign prognosis **Nursing Diagnoses (NANDA):** - Risk for Impaired Skin Integrity (related to digital ischemia) - Deficient Knowledge (related to triggers and prevention) - Anxiety (related to color changes and concern about tissue loss)

An **aneurysm** is a localized, permanent dilation of an artery beyond its normal diameter, typically defined as a 50% increase in vessel diameter. This occurs from weakening of the elastic tissue and muscular components of the arterial wall, leading to progressive enlargement. Aneurysms can rupture, causing catastrophic hemorrhage—a true surgical emergency. **Most Common Site: Abdominal Aortic Aneurysm (AAA)** The **abdominal aorta** below the renal arteries is the most common location for aneurysm formation, accounting for 80–90% of aortic aneurysms. The infrarenal location is due to the lower collagen content and greater hemodynamic stress in this segment. **Risk Factors:** - **Atherosclerosis:** The most common cause; atherosclerotic degeneration of the arterial wall - **Hypertension:** Chronic elevated pressure stresses the vessel wall - **Smoking:** Independent risk factor; tobacco damages elastic fibers - **Chronic Obstructive Pulmonary Disease (COPD):** Associated with elastic tissue destruction - **Age:** Rare before age 50; increases with age - **Male gender:** AAA is 5–10 times more common in men - **Family history:** 15–25% of AAA patients have a family history; genetic predisposition - **Other causes:** Marfan syndrome, Ehlers-Danlos syndrome (connective tissue disorders), syphilis (luetic aortitis), inflammatory aortitis **Pathophysiology:** Progressive atherosclerotic damage to the tunica media (muscular layer) and elastic lamina of the aorta leads to loss of structural integrity. Degradation of elastin and collagen by inflammatory mediators and matrix metalloproteinases (MMPs) weakens the wall. As aneurysm expands, wall tension increases according to **Laplace's law** (tension = pressure × radius), creating a vicious cycle of further expansion and wall stress. **Clinical Manifestations:** **Asymptomatic (Often Discovered Incidentally):** Many AAAs are found incidentally during abdominal imaging for other reasons. **Screening with abdominal ultrasound** is recommended for men aged 65–75 with a smoking history and men aged 60–75 with a family history of AAA. **Symptomatic (Expanding but Not Ruptured):** - **Abdominal or back pain:** Usually epigastric or left lower quadrant, constant and deep - **Pulsatile abdominal mass:** Patients or clinicians may feel an expansile pulsation in the epigastrium (felt above the umbilicus; must be distinguished from transmitted pulsation of the normal aorta) - **Bruit:** Auscultation over the aneurysm may reveal a systolic bruit from turbulent flow - **Leg edema or claudication:** From compression of iliac veins or arteries **Ruptured AAA (Surgical Emergency):** Rupture is catastrophic and life-threatening. Approximately **80% of patients with ruptured AAA die before reaching the hospital,** and mortality is 50% even with emergency surgery. **Classic Presentation of Ruptured AAA:** - **Sudden, severe abdominal or back pain** ("tearing" or "ripping" in nature) - **Hypotension** (hemorrhagic shock from massive bleeding) - **Pulsatile abdominal mass** (though often obscured by abdominal distention from blood) - **Groin or flank ecchymosis** (bruising from bleeding into tissues) - **Syncope, pallor, diaphoresis** (signs of shock) This presentation is immediately **life-threatening.** The patient requires emergency transport to the operating room for open or endovascular repair. **Diagnostic Approach:** *Imaging:* - **Abdominal ultrasound:** First-line, non-invasive; measures AAA diameter (normal aorta <3 cm; AAA typically ≥3 cm; large AAA >5.5 cm); identifies thrombus within aneurysm - **CT angiography (CTA):** Gold standard for precise measurement, location, extent, and relationship to branch vessels; essential preoperatively for surgical planning - **Magnetic resonance angiography (MRA):** Alternative in patients with contrast allergy or renal insufficiency *Laboratory:* - **Elevated LDH, low hematocrit** if rupture has occurred (indicating hemolysis from rapid bleeding) **Natural History and Indications for Intervention:** Aneurysm **size** is the strongest predictor of rupture risk: - **AAA 3.0–3.9 cm:** Rupture risk ~2%/year; surveillance ultrasound every 12 months - **AAA 4.0–4.9 cm:** Rupture risk ~3–5%/year; ultrasound every 6 months - **AAA 5.0–5.5 cm:** Rupture risk ~20%/year; consider repair (risk-benefit analysis; patient fitness for surgery) - **AAA >5.5 cm:** Rupture risk ~40%/year; **elective repair recommended** for fit patients - **Rapid expansion** (>0.5 cm in 6 months or >1 cm in 1 year): Increased rupture risk; repair considered Other indications for repair include **symptomatic aneurysm** (pain) and **concurrent aortic dissection.** **Management:** *Preoperative (Asymptomatic or Symptomatic, Expanding Aneurysm):* 1. **Blood pressure control:** **Strict reduction of aortic pressure and wall stress** to slow aneurysm expansion and reduce rupture risk - Target BP typically 110–120 mmHg systolic - **Beta-blockers** are preferred (e.g., metoprolol, atenolol) to reduce contractility and dP/dt (rate of pressure change), both of which stress the aortic wall - **ACE inhibitors/ARBs** provide additional cardioprotection - Vasodilators alone are avoided (can increase heart rate and contractility, worsening wall stress) 2. **Risk factor modification:** - **Smoking cessation:** Urgent; slows aneurysm growth - Dyslipidemia management (statins) - Diabetes control - Optimization of pulmonary and cardiac function 3. **Antiplatelet therapy:** Aspirin (reduces cardiovascular events) 4. **Surveillance:** Serial imaging (ultrasound or CT) to track growth and guide intervention timing *Surgical Repair:* Two main approaches: 1. **Open surgical repair:** Traditional approach - **Advantages:** Definitive, durable, long-term success - **Disadvantages:** Major surgery, longer hospitalization, higher perioperative morbidity/mortality - **Procedure:** Under general anesthesia, the aorta is exposed, cross-clamped above and below the aneurysm, and a graft (synthetic or autogenous vein) is sutured in place of the aneurysm - **Complications:** Graft infection, thrombosis, false aneurysm at anastomoses, aortoenteric fistula (late), paralysis from spinal cord ischemia (rare) 2. **Endovascular aneurysm repair (EVAR):** Minimally invasive - **Advantages:** Smaller incisions, shorter procedure, faster recovery, lower perioperative mortality (especially in high-risk patients) - **Disadvantages:** Requires specific anatomy, higher rate of reintervention, requires lifelong imaging surveillance, risk of endoleak (blood persisting outside the graft but inside the aneurysm sac) - **Procedure:** A stent-graft is placed via the femoral or iliac artery under fluoroscopic guidance; the graft excludes the aneurysm from arterial pressure - **Types of endoleak (major complication):** - **Type I:** Flow from inadequate seal at proximal or distal graft attachment; often requires intervention - **Type II:** Retrograde flow from branch vessels (lumbar arteries, inferior mesenteric artery); often self-limiting - **Type III:** Defect in the graft material; requires intervention - **Type IV:** Graft porosity; usually resolves - **Type V:** Endotension (pressure within aneurysm sac without visible endoleak); rare **Rupture: Emergency Management:** - **Immediate action:** Call emergency services; establish large-bore IV access (two if possible); **do NOT delay for imaging** if rupture is clinically obvious (severe pain, shock, pulsatile mass) - **Permissive hypotension:** Maintain **systolic BP 90–100 mmHg** during transport and in ED to avoid further bleeding from the aneurysm (raising BP increases bleeding). Aggressive fluid resuscitation before hemorrhage control can worsen outcomes ("damage control" philosophy). - **Massive transfusion protocol:** Prepare for significant blood loss; type and cross-match; have blood products immediately available - **Emergency surgery:** Patient is rushed to the operating room for urgent open or endovascular repair (EVAR may be faster in some centers with 24/7 availability) **Nursing Assessment and Management:** *Preoperative (Asymptomatic or Expanding AAA):* 1. **Assessment:** Palpate abdomen gently for a pulsatile mass **above the umbilicus** (distinguishes AAA from transmitted aortic pulsation at or below umbilicus). Measure diameter if visible on ultrasound. Assess for pain, risk factors, and cardiopulmonary fitness. 2. **Key Nursing Intervention:** **AVOID VIGOROUS PALPATION OF A KNOWN PULSATING ABDOMINAL MASS.** Excessive pressure can trigger rupture. Gentle palpation for documentation is acceptable; explain to the patient that the mass is being monitored carefully. 3. **Monitoring:** Track aneurysm size on serial imaging; educate patient on warning signs of rupture (sudden severe abdominal/back pain, syncope). 4. **Preoperative preparation:** Baseline labs (CBC, coagulation studies, blood typing), cardiac clearance if indicated, pulmonary assessment, nutritional optimization. 5. **Patient education:** Explain elective repair vs. surveillance based on size; discuss risks and benefits; clarify that asymptomatic aneuryms don't always require surgery (size-dependent). *Perioperative (Day of Surgery):* 6. **Preoperative:** NPO status, IV access, premedication, transport to OR; **ensure informed consent is obtained.** 7. **Postoperative (Open Repair):** Intensive care unit (ICU) monitoring; continuous cardiac monitoring; frequent vital signs; assess **peripheral pulses bilaterally** (femoral, DP, PT) to ensure graft patency and distal perfusion; monitor **urine output closely** (indicator of renal perfusion; oliguria suggests renal ischemia from cross-clamping or surgical manipulation); assess for **abdominal distention, tenderness, fever** (signs of graft infection); **pain control**; DVT prophylaxis (sequential compression devices, early ambulation); monitor for respiratory compromise (pain limiting deep breathing increases pneumonia risk). 8. **Postoperative (EVAR):** Similar monitoring; additionally assess **groin incision sites** (potential bleeding, hematoma); educate that **lifelong imaging surveillance** is needed to detect endoleak and aneurysm sac growth. *Ruptured AAA (Emergency):* 9. **Immediate actions:** Rapid transport to OR; establish vascular access and massive transfusion protocol; monitor continuously; support family; prepare for potential death (high mortality despite intervention). **Nursing Diagnoses (NANDA):** - Risk for Decreased Cardiac Output (related to potential rupture and hemorrhage) - Acute Pain (related to aneurysm expansion or rupture) - Risk for Infection (related to surgical repair) - Deficient Knowledge (related to surveillance, risk factors, warning signs) - Fear and Anxiety (related to life-threatening diagnosis) **Patient Education:** - **For asymptomatic or surveillance AAA:** Explain that size determines rupture risk and need for surgery; attend all imaging appointments; report any abdominal or back pain, syncope, or signs of shock immediately. - **For elective repair:** Discuss risks and benefits; postoperative expectations (pain, activity restriction, recovery timeline); importance of medications (beta-blockers, antiplatelets). - **For EVAR patients:** Emphasize need for **lifelong imaging follow-up** to detect graft complications; report any groin pain, swelling, or infection. - **Risk factor modification:** Smoking cessation is critical; BP control, cholesterol management, diabetes control. - **Activity:** Avoid heavy lifting and strenuous activity post-op per surgeon guidelines; gradual return to normal activities.